Thursday, September 18, 2014 Last update: 6:33 AM - All Company Technology News Since 1996

Cellectis: Genome Engineering & CART Cells: At the Forefront of Immuno-Oncology

Companies mentioned in this article: Cellectis

Regulatory News:

NEW YORK -- (BUSINESS WIRE) -- Cellectis (Alternext: ALCLS.PA), a leader in the development of adoptive immunotherapies based on engineered allogeneic CART cells (UCART) will host a R&D/ Analyst Day on Thursday, September 11 at 7:30AM in New York City. Cellectis’ scientists will provide an overview of the Company's therapeutic innovations. The event will also feature presentations by key opinion leaders: Pr. Laurence Cooper, MD Anderson Cancer Center ; Dr. Jaume Pons Senior Vice President and CSO of Rinat, the biotech unit of Pfizer and Eric Falcand, Director, Alliance Management & US Licenses at Servier Laboratories.



8:00 Welcome Remarks
Dr. André Choulika, Ph.D. – Chairman & CEO of Cellectis

8:05 Keynote address – Pr. Laurence Cooper, MD, Ph.D. – University of Texas, MD Anderson Cancer Center, Houston, Texas (25mn)

8:30 The Discovery at Cellectis
Dr. Philippe Duchateau, Ph.D. – Chief Scientific Officer (10 mn)

8:40 Genome Engineering Technologies
Dr. Julien Valton, Ph.D. – Project Leader (20 mn)

9:00 Editing the T Cell Genome
Dr. Laurent Poirot, Ph.D. – Head of Early Discovery (20 mn)

9:20 Dr. Jaume Pons, Ph.D. – Senior Vice President and Chief Scientific Officer of Rinat, the biotech unit of Pfizer, San Francisco, California (15 mn)

9:35 CAR architecture & CAR application
Dr. Alexandre Juillerat, Ph.D. – Project Leader (20 mn)

9:55 BREAK

10:05 About UCART19 and UCART123
Dr. Julianne Smith, Ph.D. – Vice President, CART Development (20 mn)

10:25 Eric Falcand – Director, Alliance Management & US Licenses at Servier Laboratories (15 mn)

10:40 Manufacturing & Regulatory
Stéphan Reynier – Head of Regulatory (15 mn)

10:55 Closing remarks and future perspectives for our allogeneic technology
Dr. Mathieu Simon, MD – Executive Vice President (20 mn)


Please RSVP with
Cellectis /Jennifer Moore
The Trout Group /Simon Harnest P: +1-646-378-2919

Location: Le Parker Meridien Hotel - 119 West 56th Street - NEW YORK
Time: 7:30 -11:45 AM
Upon invitation – limited seats available

About Cellectis

Cellectis is a biopharmaceutical company focused on oncology. The company’s mission is to develop a novel generation of therapy based on engineered T-cells to treat cancer. Cellectis capitalizes on its 14 years of expertise in genome engineering, based on TALEN™, meganucleases and the state-of-the-art electroporation technology Pulse Agile, to create a new generation of cancer immunotherapy for treating leukemias and solid tumors. Cellectis adoptive cancer immunotherapy for chronic and acute leukemias is based on the first allogeneic T-cell chimeric antigen receptor (CAR) technology. CAR technologies are designed to target surface antigens expressed on cells. These treatments reduce toxicities associated with current chemotherapeutics and have the potential for curative therapy. The Cellectis Group is focused on life sciences and uses leading genome engineering technologies to build innovative products in various fields and markets. Cellectis is listed on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website:


This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements.

Copyright © Business Wire 2014

Jennifer Moore
The Trout Group
Simon Harnest, +1-646-378-2919